GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Short Percentage of Float

ProKidney (MEX:PROK) Short Percentage of Float


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ProKidney's Short Percentage of Float

For the Biotechnology subindustry, ProKidney's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where ProKidney's Short Percentage of Float falls into.


ProKidney (MEX:PROK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Short Percentage of Float
Comparable Companies
PRLD SEER MLEC SGMO INO CDXC AAGH AADI ANIX VXRT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
PROK:USA
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
Website
https://www.prokidney.com
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.